Computational design of Matrix Metalloproteinase-9 (MMP-9) resistant to auto-cleavage
Biochemical Journal · 2023
DOI: 10.1042/bcj20230139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Journal, 2023. Verfasst von Alessandro Bonadio und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Matrix Metalloproteinase 9, Endopeptidases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, BSF- US Israel Binational Science foundation, Israel Science Foundation.
Abstract (Originalsprache)
Matrix metalloproteinase-9 (MMP-9) is an endopeptidase that remodels the extracellular matrix. MMP-9 has been implicated in several diseases including neurodegeneration, arthritis, cardiovascular diseases, fibrosis and several types of cancer, resulting in a high demand for MMP-9 inhibitors for therapeutic purposes. For such drug design efforts, large amounts of MMP-9 are required. Yet, the catalytic domain of MMP-9 (MMP-9Cat) is an intrinsically unstable enzyme that tends to auto-cleave within minutes, making it difficult to use in drug design experiments and other biophysical studies. We set our goal to design MMP-9Cat variant that is active but stable to auto-cleavage. For this purpose, we first identified potential auto-cleavage sites on MMP-9Cat using mass spectroscopy and then eliminated the auto-cleavage site by predicting mutations that minimize auto-cleavage potential without reducing enzyme stability. Four computationally designed MMP-9Cat variants were experimentally constructed and evaluated for auto-cleavage and enzyme activity. Our best variant, Des2, with 2 mutations, was as active as the wild-type enzyme but did not exhibit auto-cleavage after 7 days of incubation at 37°C. This MMP-9Cat variant, with an identical with MMP-9Cat WT active site, is an ideal candidate for drug design experiments targeting MMP-9 and enzyme crystallization experiments. The developed strategy for MMP-9CAT stabilization could be applied to redesign other proteases to improve their stability for various biotechnological applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
- Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel.
ORCID-Profile: Alessandro Bonadio, Julia Shifman
Förderung
- NCI NIH HHS
- BSF- US Israel Binational Science foundation
- Israel Science Foundation
- NIH NCI
- Israel Cancer Research Fund
- U. of Toronto/HUJI research alliance in protein engineering
Zitieren
APA
Bonadio, A., Oguche, S., Lavy, T., Kleifeld, O., & Shifman, J. (2023). Computational design of Matrix Metalloproteinase-9 (MMP-9) resistant to auto-cleavage. Biochemical Journal. https://doi.org/10.1042/bcj20230139
Vancouver
Bonadio A, Oguche S, Lavy T, Kleifeld O, Shifman J. Computational design of Matrix Metalloproteinase-9 (MMP-9) resistant to auto-cleavage. Biochemical Journal. 2023. doi:10.1042/bcj20230139
BibTeX
@article{Bonadio2023,
author = {Bonadio, Alessandro and Oguche, Solomon and Lavy, Tali and Kleifeld, Oded and Shifman, Julia},
title = {Computational design of Matrix Metalloproteinase-9 (MMP-9) resistant to auto-cleavage},
journal = {Biochemical Journal},
year = {2023},
doi = {10.1042/bcj20230139}
}
EUVIMED